Government increases ZAMMSA funding to boost access to sickle cell medication

The Government has increased funding to the Zambia Medicines and Medical Supplies Agency (ZAMMSA) in a bid to improve access to essential medication, particularly for patients living with Sickle Cell Disease (SCD).

Health Minister Hon. Elijah Muchima made the announcement in response to growing concerns from the Sickle Cell community over the limited availability and high cost of life-saving medication such as Hydroxyurea.

Speaking during the 2025 World Sickle Cell Day Commemoration in Lusaka, Hon. Muchima acknowledged the challenges faced by patients and emphasized the government’s commitment to strengthening medical supply systems. He noted that while general medication is being procured through ZAMMSA, certain specialized treatments may not always be readily available within the public health system.

“In such instances, the government can facilitate access to care through the Specialist Medical Services and Assistance (SAMHSA) program, which supports cases requiring advanced interventions,” said Hon. Muchima.

He also urged patients to leverage the National Health Insurance Management Authority (NHIMA) for broader access to medical services.

Meanwhile, Changala Mwanza, founder of the Lukumontambo Foundation, a local Sickle Cell advocacy group, lamented the high cost and inaccessibility of Hydroxyurea. She said many patients are unable to adhere to treatment due to financial constraints.

“The medication is either unavailable or too expensive when found. This threatens the well-being of those living with SCD,” Mwanza said.

GroundTruth Zambia | 4th July, 2025.